The problem with matritech is not false positives. They have had great success at detection and false positive rates. The problem is the number of patients they can test and the length of time it takes to do those tests. The success of matritech depends more on their partners being able to create mass spec then it does on the success of the NMP's.
I own a small stake in this company but I'am not holding my breath.
Market Data 
Markets 
AI
